Investor Presentaiton
Strategic priorities
ESTELLEⓇ
Support marketing partners to realize growth potential
Continued clinical development to support product
differentiation
DONESTAⓇ
Complete NDA filing with FDA
Establish optimal U.S. marketing agreement
Perform additional clinical Phase 2 studies
Hair
Skin
Sexual desire
Estetrol (E4)
New indications in women's health for fertility
IVF implantation exploratory clinical studies on
endometrial thickening
New pharmacoecenomic Phase 2 and Phase
4 studies
Estetrol (ESTELLE® / DONESTAⓇ) safety in br
east cancer & blood clotting
Additional imperatives
.
Debt consolidation
•
Better leverage CDMO
•
Options for Novalon complex therapeutics business
Acquire preclinical and/or clinical opportunities
Mithra Investor Presentation - November 2023View entire presentation